Allergology International

Allergology International

Volume 71, Issue 4, October 2022, Pages 459-471
Allergology International

Invited Review Article
Executive summary: Japanese guidelines for allergic conjunctival diseases 2021,

https://doi.org/10.1016/j.alit.2022.07.005Get rights and content
Under a Creative Commons license
open access

Abstract

Allergic conjunctival disease (ACD) is an inflammatory disease of the conjunctiva that is mainly caused by type I hypersensitivity response to allergens and accompanied by subjective symptoms and other findings induced by antigens. ACD is classified as allergic conjunctivitis, atopic keratoconjunctivitis, vernal keratoconjunctivitis, and giant papillary conjunctivitis. This article summarizes the third edition of the Japanese guidelines for allergic conjunctival diseases published in 2021 and outlines the diagnosis, pathogenesis, and treatment of ACD.

Since the introduction of immunosuppressive eye drops, the treatment strategies for severe ACDs have significantly changed. To clarify the recommended standard treatment protocols for ACD, the advantages and disadvantages of these treatments were assessed using clinical questions, with a focus on the use of steroids and immunosuppressive drugs. This knowledge will assist healthcare providers and patients in taking an active role in medical decision making.

Keywords

Allergic conjunctivitis
Atopic keratoconjunctivitis
Cyclosporine
Tacrolimus
Vernal keratoconjunctivitis

Cited by (0)

This article is based on the Japanese Guidelines for Allergic Conjunctival Diseases, 3rd edition, in Japanese published in 2021. Available at: https://www.nichigan.or.jp/member/journal/guideline/detail.html?itemid=429&dispmid=909.

Peer review under responsibility of Japanese Society of Allergology.